Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy

Rationale: The sustained and severe endoplasmic reticulum (ER) stress in cancer cells may contribute to apoptotic cell death, thus representing a potential target for cancer therapy. Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhe, Gao, Wei, Zhou, Li, Chen, Yan, Qin, Siyuan, Zhang, Lu, Liu, Jiayang, He, Yujia, Lei, Yunlong, Chen, Hai-Ning, Han, Junhong, Zhou, Zong-Guang, Nice, Edouard C., Li, Changlong, Huang, Canhua, Wei, Xiawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691391/
https://www.ncbi.nlm.nih.gov/pubmed/31410188
http://dx.doi.org/10.7150/thno.36254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691391/
https://www.ncbi.nlm.nih.gov/pubmed/31410188
http://dx.doi.org/10.7150/thno.36254

Ejemplares similares